Sulfanilamide has long been widely recognized for its usefulness in anti-bacterial treatment medicine. As one of the earliest known antibiotics, Sulfanilamides, or Sulfa drugs as they are popularly called, were thought to produce impressive results in people without much trouble. And it would remain the popular sentiment until a public health incident with disastrous consequences took place in 1937.
This incident, discussed later in this blog, would spark a hot debate and mark a revolution in the drug safety subject. It has become central to discussions about drug safety in pharmacovigilance certification programs worldwide. And if you’re pursuing a career in such a line, we have discussed a few things that’ll surely interest you in this blog.
The 1937 Elixir Sulfanilamide Disaster
In 1937, a series of tragic incidents were recorded in the US, and they would eventually change the face of the pharmaceutical industry forever. The deaths of more than a hundred people, mostly children, were traced to the ingestion of the antibiotic Sulfanilamide, a sulfonamide antibacterial drug in liquid form. This antibiotic was found to have been prepared with diethylene glycol, a poisonous solvent.
As you’ll discover in pharmacovigilance training, diethylene glycol, a poisonous solvent, was used to manufacture Sulfanilamide.
The unfortunate incident would trigger a wave of reactions that cast an increased spotlight on lax drug safety testing. It would eventually lead to a revolution in drug safety and pharmacovigilance programs and the passage of the landmark Federal Food, Drug, and Cosmetic Act of 1938.
This landmark act enforced stricter drug safety laws, reinforcing drug regulation, testing, and oversight to ensure public health safety. Several other countries would adopt similar versions of this act in the wake of the 1937 disaster, albeit at different times. Canada’s Food and Drugs Act of 1953 would later follow a similar path to its US counterpart.
The State Of Sulfanilamides In Pharmacovigilance Training and Drug Safety Today
Drug safety (along with testing for quality and efficacy) has become a focal point of all drug testing endeavours, even featuring heavily in pharmacovigilance courses. Greater surveillance has been placed on drug development, extending to the post-marketing stage. Clinical trials have become a global necessity, with human-based testing becoming a key requirement for these procedures.
The Sulfanilamide incident brought a renewed focus on drug safety and pharmacovigilance.
Many countries now require their Drug and Food Administration agencies to collect proof of the safety of new drugs before they can be approved for public use. While some of the aforementioned activities or laws were available before the 1937 disaster, many of them received increased attention after it. Pharmacovigilance would become an industry player, and pharmaceutical products were only allowed to hit the market after being certified fit for public use.
While Sulfanilamides and other Sulfonamides have received an increased spotlight from drug testing Czars worldwide, they continue to play an important role in antibacterial treatment. Sulfa drugs still feature in many medicines today due to their proven antibacterial capacity, but they are taken with greater care. Many food and drug products in use today only ever contain these compounds below a Maximum Residue Level(MRL), as instituted by such public health agencies as Health Canada, for example.
As you’ll discover in pharmacovigilance training, the Sulfanilamide disaster forced a rethinking of lax drug safety laws.
These MRLs translate to safe dosages of sulfonamide and can be found in many veterinary drugs today. So while the infamous 1937 disaster was a truly tragic event, it leaves us with important lessons about drug safety. It is an unforgettable reminder of the fatal consequences that can result from the failure of surveillance, safety testing, and accountability in drug development.
Do you desire to get Pharmacovigilance training?
Explore the Pharmacovigilance diploma program at AAPS.